Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 3/20 | 0.51 |
| ▸ | DGAT1 | O75907 | 9/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | COMT | P21964 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17868458 | 0.84 | DGAT1 (0.50) | SCN2ADGAT1TRPV1COMT | |
| SCHEMBL11260682 | 0.82 | DGAT1 (0.40) | SCN2ADGAT1 | |
| SCHEMBL17678002 | 0.82 | DGAT1 (0.49) | SCN2ADGAT1TRPV1COMT | |
| SCHEMBL17868402 | 0.82 | DGAT1 (0.53) | SCN2ADGAT1 | |
| SCHEMBL9940238 | 0.82 | TRPV1 (0.62) | SCN2ADGAT1TRPV1COMT | |
| SCHEMBL3584568 | 0.81 | SCN2A (0.58) | SCN2ADGAT1NPY5R | |
| SCHEMBL11245211 | 0.80 | HRH1 (0.56) | SCN2ANPY5R | |
| SCHEMBL12499046 | 0.79 | DGAT1 (0.46) | SCN2ADGAT1TRPV1COMT | |
| SCHEMBL23847030 | 0.78 | DGAT1 (0.59) | SCN2ADGAT1 | |
| SCHEMBL18865669 | 0.78 | DGAT1 (0.49) | SCN2ADGAT1NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727549-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | University of Georgia Research Foundation, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIV GEORGIA (US) | 2026-04-09 | — | — | US | disclosed |
| WO-2024258900-A2 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | AMATHUS THERAPEUTICS, INC. (US) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174523-A1 | BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF | TRAP1, PINK1, TP53BP1 | SCN2A 818/4885DGAT1 3633/4885NPY5R 3221/4885 |
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | SUB1, PFN1, HCCS | SCN2A 2686/4885DGAT1 1115/4885NPY5R 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.